Drug Hunter has launched Molecule Search, a unified structure search platform that allows researchers to simultaneously query FDA-approved drugs, clinical compounds, recent disclosures and indexed molecules. The update consolidates previously disconnected workflows into a single interface. The platform pairs chemical structures with biological context, including indexed targets, mechanisms of action, 3D structure information and therapeutic areas. Key features include parallel 2D molecular property searches, biological context for chemical matter, referenceable compound and protein structural data, and visual landscape tools for analysing chemical space. Founded by scientists, Drug Hunter serves over 200 biotech and pharmaceutical organisations worldwide. The company aims to reduce the time researchers spend assembling data by integrating chemical structure and biological context into single queries. Molecule Search is now available to all Drug Hunter members.

Drug Hunter, a drug discovery knowledge platform, secured a significant seed investment from Teamworthy Ventures to enhance its research capabilities. This investment will help expand Drug Hunter's platform with improved analytics, broader scientific coverage, and a new mobile app. The platform is praised for aiding informed decision-making in pharmaceutical R&D, with testimonials highlighting its impact on drug design and collaboration.